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This information sheet is aimed at health professionals and aims to answer 20 Frequently Asked 
Questions about cannabis.  Cannabis and cannabis-based products are becoming more widespread 
within Ireland. People who use the mental health services, both children and adults are at higher 
vulnerability to the harms of cannabis use. Health professionals should be familiar with these risks as 
the media as well as patients are likely to underestimate the harms of cannabis use. 
 
• Cannabis is the mostly commonly used illegal drug in Ireland 
• Cannabis is easily available in Ireland including high potency versions 
• Cannabis adversely affects mental health 
• Young people who use high potency cannabis regularly are at highest risk of harms 
• Cannabis can be additive  
• Cannabis and cannabis products are not evidence-based treatments for mental illness 
• Cannabis use is associated with many social and educational problems  
 
 
Frequently Asked Questions 
 
1. What is Cannabis? 
Cannabis is a psychoactive drug derived from a genus of plants of the same name.  Cannabis is most 
commonly available in Ireland in the form of herbal cannabis (“weed”, “grass”) or cannabis resin 
(“hashish” or “hash”). There are also high potency cannabis extracts, such as oil, shatter or wax. The 
majority of cannabis use in Ireland is via smoking1. Cannabis products can also be inhaled via vaping 
or “dabbing” or ingested orally (“edibles”).  
 
2. Is Cannabis use common in Ireland? 
Cannabis is the most widely used illegal drug in Ireland. The National Advisory Committee on Drugs 
and Alcohol (NACDA)1 conducted a general population study in 2014/2015 and found 1 in 4 of 
respondents had used cannabis at least once in their lifetime with 6.5% of respondents reporting 
cannabis use within the last month. Cannabis use is highest in young adults, and regular use is more 
common among males than females. Results from the European School Survey Project on Alcohol 
and Other Drugs (ESPAD)2 study in 2019 showed that 9% of Irish Transition Year Students (aged 15-
16) in Ireland had used cannabis in the past month. 
 
3. What are Cannabinoids? 
Cannabis contains over one hundred cannabinoids, the two most researched are the 
phytocannabinoids delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Cannabinoids exert 
their effects primarily by interacting with the endocannabinoid system, which comprises 
endogenous ligands such as N-arachidonoylethanolamide and 2-arachidonoylglycerol. There are two 
specific receptors - cannabinoid receptor type-1 (CB1) and cannabinoid receptor type-2 (CB2). A 
large number of synthetic cannabinoids also exist designed to imitate the actions of THC with a 
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4. What are the effects of THC and CBD? 
The two cannabinoids act quite differently with different affinity for the different cannabinoid 
receptors. THC is the psychoactive substance responsible for the “high” and can lead to dependence. 
THC can cause hallucinations, paranoid thoughts and agitation. THC is also associated with 
impairment of cognition and thinking both in the short term and the long term. THC is a partial 
agonist at the CB1 receptor4. CB1 receptors are found across the brain with high concentrations in 
the neocortex, basal ganglia and hippocampus5. CBD is not thought to be associated with 
dependence or psychosis and has a mildly sedating effect. CBD lacks significant affinity for the CB1 
receptor but it is able to displace THC at low concentrations6.  
 
5. How much THC is available in the Cannabis in Ireland? 
Cannabis with THC content greater than  9% is generally considered “high-potency” cannabis. The 
international and European trend shows that THC content in both herbal cannabis and resin is 
increasing7,8. The THC level of cannabis seized in Ireland is not routinely measured but is expected to 
be in line with European trends. In 2010 samples of cannabis in Ireland were tested and the THC 
content ranged from 1 – 16%9. Evidence from the US indicates that potency of cannabis products 
has increased following legalisation10,11.  
 
6. Why does the THC level matter? 
The adverse psychoactive effects of cannabis are attributed to the THC component. Studies show 
that the higher the THC content the greater the risk of psychosis, agitation and anxiety developing3.  
 
7. What are the acute effects of cannabis? 
For the majority of users, the effects of cannabis intoxication are acute and transient. Many users 
report pleasurable effects including mild euphoria and a feeling of relaxation.  Undesirable 
experiences (particularly with high potency cannabis) include panic attacks, dysphoria, 
suspiciousness and paranoia, perceptual distortions, hallucinations, cognitive impairment and 
psychomotor impairment3,12. 
 
8. What are effects of cannabis on driving?  
The cognitive and psychomotor effects of cannabis account for impairment of driving and operating 
machinery13. The combination of alcohol and cannabis intoxication has a synergistic effect on driving 
impairment which exceeds the risk of using either exclusively14.  The Gardaí began roadside testing 
for cannabis and other substances in 2016. In 2018 cannabis was implicated in 1,205 cases of road 
traffic offences according to the Medical Bureau of Road Safety. A recent study suggests that chronic 
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9. Is Cannabis addictive? 
Yes, cannabis is addictive and can lead to Cannabis Use Disorder. Stopping cannabis consumption 
after a period of use can result in significant withdrawal effects (irritability, anxiety, decreased 
appetite, restlessness, and sleep disturbance)16.  
 
The 2014/15 Drug Prevalence Survey conducted by the National Advisory Committee on Drugs and 
Alcohol1 found that 1 in 5 people who use cannabis report symptoms consistent with cannabis 
dependence. This rate of cannabis use disorder is consistent with international findings and can 
increase to 1 in 3 in the case of adolescent users who use large amounts of cannabis17.A cannabis 
use disorder is now the most common presenting problem for people seeking addiction treatment 
under the age of 25 years, even more common than alcohol use disorder18. From 2006-2016 there 
was a two-fold increase in adolescents entering the addiction service for treatment of a cannabis use 
disorder18. The risk of dependence increases with increased frequency of use and higher potency 
cannabis. A review based on US data showed early use is a predictor of dependence, people who 
begin using cannabis before age 18 are four to seven times more likely to develop a cannabis use 
disorder19. 
 
10. Is Cannabis a gateway drug? 
The gateway hypothesis proposes that cannabis use leads to use of other drugs such as cocaine, 
amphetamine and heroin. Although scientific evidence is mixed on this question, a recent large 
study of predictors of later opioid use disorder in the US has shown that early cannabis use (before 
age 18) was the dominant predictor20. An Australian twin study showed that twins who started using 
cannabis by age 17 were 2-5 times more likely than their non-cannabis using co-twin to go on to use 
other substances and to become dependent on drugs or alcohol21. 
 
11. Is Cannabis associated with mental illness? 
Yes. Cannabis use can precipitate new mental illness and exacerbate pre-existing mental illness. A 
study18 using the National Psychiatric In-Patient Reporting System (NPIRS) data found that cannabis-
related admissions had increased by 140% between 2011 and 2017 for people aged 15-34.   
 
Psychosis 
Cannabis users are at a 3-4 fold increased risk of development of acute psychosis22 with evidence 
that this association is increased to 5-6 fold with early use of high potency cannabis23.  People with 
cannabis-induced psychosis are at high risk of progression to a chronic psychotic disorder such as 
schizophrenia. It has been shown that 1 in 5 people who suffer cannabis-induced psychosis will 
progress to a schizophrenia diagnosis within 3-4 years24.  
 
Mood Disorders 
Early-onset use of cannabis is also associated with an increased risk of development of major 
depressive disorder25,26. Cannabis use disorder has been associated with a greater risk of Bipolar 
affective disorder onset27 and reduced length of time between relapses.  
 
Anxiety Disorders 
Young cannabis users are at higher risk of anxiety disorders particularly those who use high potency 
cannabis28.  
 




Chronic cannabis users are more likely to report thoughts of suicide than non-users. The National 
Self-Harm Registry Ireland Annual Report 2018 states that cannabis was the most common illicit 
drug used among men aged 15-24 with self-harm presentations – present in 8% of overdose acts29. A 
recent systematic review found that the risk for suicide attempts in young cannabis users was more 
than 3 times higher than in young people who did not use cannabis26. 
 
12. What are the risk factors for developing chronic psychosis for cannabis users? 
The use of high potency (high THC) cannabis regularly and starting to use cannabis at an early age 
are the strongest risk factors for developing a psychotic disorder among cannabis users30. Other 
important risk factors are a family history of psychosis and individual genetic vulnerabilities. 
THC has been shown to induce psychosis in healthy people with no history of mental illness12. The 
Report from the National Academies of Science, Engineering and Medicine (2017) has stated that 
cannabis use is associated with psychosis:  higher the dose, the higher the risk27. 
 
13. Do the risks of cannabis apply only to people who use excessively? 
The highest risk is for users of high potency cannabis on a regular basis. However, studies have 
shown that even a small amount of cannabis exposure in early adolescence may be related to 
structural brain changes and mental illness31. 
 
14. How does cannabis influence the developing brain? 
Cannabis use has effects on brain structure and development32,33. The adolescent brain seems to be 
most at risk from neurodevelopment and structural changes30. Cannabis has an effect on synaptic 
pruning and white matter brain development and users with a “still developing brain” are at most 
risk30,34. While chronic and high frequency use of cannabis is associated with structural brain 
differences a recent review has shown that even low exposure to cannabis during adolescence may 
result in changes in grey matter volume in the brain31. Larger studies and further replication are 
required to investigate this relationship.  
 
15. Is cannabis use in pregnancy harmful?  
Cannabis use during pregnancy is associated with low birth weight and disruption of the 
endocannabinoid system which may lead to neurodevelopmental problems35 including autism 
spectrum disorder36. For these reasons, cannabis should be avoided in pregnancy.  
 
16. What about cognition, motivation and academic attainment? 
Cannabis use can adversely influence academic and work performance and is linked to decreases in 
IQ in those who use cannabis heavily at a young age37ab. A recent systematic review of the evidence 
reports average decline of approximately 2 IQ points following exposure to cannabis in youth38. 
Cannabis use decreases memory performance tasks in students39. Multiple studies across different 
sites have shown early life cannabis use, is strongly associated with poorer educational outcomes, 











17. Can cannabis use result in harm to others? 
Yes, cannabis use is associated with harms for the user, their family and the society they live in. All 
parental addictions, including cannabis use disorder, are now recognised as constituting an adverse 
childhood experience (ACE) and children growing up with increased ACEs have poorer health and 
socioeconomic outcomes42,43. A severe cannabis use disorder can lead to parenting problems, and 
neglect of children. The HSE and TUSLA have issued a joint advisory document on addressing these 
hidden harms of substance use disorders which has practical advice on problem drug use within 
households44.  
  
Cannabis use has also been implicated in many road traffic accidents. In the US, the states that 
legalised recreational cannabis sales had higher traffic fatalities in the year following legislation 
change45. Cannabis use increases the risk of violent behaviour46, especially in individuals with 
psychotic disorders47. Cannabis use is also implicated in domestic violence and in cases where 
children are exposed to violence48,49. Teenagers and young adults with cannabis use disorders can 
cause substantial distress to their parents and siblings50, and clinical services in Ireland and 
elsewhere note that child-to-parent violence occurs frequently in these situations51.  
 
18. Can cannabis be used to treat mental illness? 
A comprehensive recent review found that cannabis-based products are not effective in the 
treatment of mental illnesses (e.g. psychosis, depressive disorders, anxiety disorders, post-traumatic 
stress disorder and Tourette’s syndrome), and were associated with adverse side effects52. There is 
concern that people with mental illnesses may self-medicate with cannabis, or have it unwisely 
recommended to them, and this may delay both appropriate help-seeking and provision of 
evidence-based treatments. At time of publication cannabis and cannabis products are not evidence-
based treatments for mental illness. Studies are ongoing to investigate whether cannabidiol (CBD) 
may be used in the treatment of schizophrenia and substance dependence. There are no definitive 
results as yet.  
 
19. What are the physical harms associated with cannabis use? 
Cannabis smoke contains similar toxins to those found in tobacco smoke (e.g. carbon monoxide, 
aldehydes, acrolein, phenols and carcinogenic polycyclic aromatic hydrocarbons)53. In Irish general 
hospitals, it has been noted that there was a three-fold increase in the number of admissions of 
young adults with a cannabis related diagnosis between 2005 and 201718. Cannabis use is associated 
with physical harms including: cannabis hyperemesis syndrome54, exacerbation of respiratory 
illnesses including bronchitis55,56, cardiovascular illness including stroke and cardiac arrhythmias and 
certain types of cancer57,58. 
 
A scoping review of 72 systematic reviews concerning the benefits and harms of medical cannabis 
found mild harms were frequently reported. The authors state the harms of cannabis-based 
medicines may outweigh the benefits60.   
 
20. Many cannabis users express the view that cannabis consumption is beneficial to 
their mental health. How do you explain this? 
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In common with other substances, including alcohol, many people experience the short-term effects 
as pleasurable. Survey data both nationally and internationally would suggest the perception of the 
harms of cannabis have diminished over recent years especially among adolescents18.  Current 
research is on-going to assess and understand this trend. Possible factors include favourable media 
coverage of cannabis use, misunderstanding and misrepresentation of the early evidence on 
cannabis-based products as therapeutic agents, social media misinformation and effects of 
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